Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
InfuSystem Holdings ( (INFU) ) has shared an update.
At its 2026 Annual Meeting of Stockholders held on May 11, 2026, InfuSystem stockholders approved a Third Amendment to the 2021 Equity Incentive Plan, lifting the maximum shares of common stock reserved under the plan to 7,000,000. The plan, administered by the Board’s Compensation Committee, enables a wide range of equity and cash awards for employees, consultants, and directors, reinforcing the company’s ability to use equity-based compensation to attract and retain talent.
At the same meeting, all seven board nominees were elected, executive compensation was approved on an advisory basis, and the amendment to increase authorized shares under the 2021 Equity Plan received stockholder backing. Stockholders also ratified Grant Thornton LLP as independent auditor for the fiscal year ending December 31, 2026, signaling continued shareholder support for the company’s governance, compensation framework, and financial oversight.
The most recent analyst rating on (INFU) stock is a Buy with a $17.50 price target. To see the full list of analyst forecasts on InfuSystem Holdings stock, see the INFU Stock Forecast page.
Spark’s Take on INFU Stock
According to Spark, TipRanks’ AI Analyst, INFU is a Neutral.
The score is anchored by improved profitability and solid cash generation, reinforced by guidance for continued pro forma growth and margin expansion. It is held back by a weak technical backdrop (price below key moving averages with negative MACD) and an expensive valuation (high P/E with no dividend support), alongside near-term revenue headwinds from the GE contract restructuring and ERP-related cost/cash-flow pressures.
To see Spark’s full report on INFU stock, click here.
More about InfuSystem Holdings
InfuSystem Holdings, Inc. operates in the healthcare sector, providing infusion therapy-related products and services. The company supports patients, providers, and payers through equipment, supplies, and related services, with its workforce including employees, consultants, and directors across the organization and its affiliates.
Average Trading Volume: 127,438
Technical Sentiment Signal: Sell
Current Market Cap: $169.8M
Learn more about INFU stock on TipRanks’ Stock Analysis page.